Everest Medicines Signs Exclusive Agreement to Develop and Commercialize LNZ100 in Greater China
Key Highlights for Investors
- Exclusive Agreement Signed: On 5 June 2026, Everest Medicines Limited (“Everest”) entered into an exclusive agreement with Corxel Pharmaceuticals Hong Kong Limited, a subsidiary of Corxel Pharmaceuticals Limited (“CORXEL”), to develop, manufacture, and commercialize LNZ100 in Greater China, which covers mainland China, Hong Kong, Macau, and Taiwan.
- Financial Terms: The agreement involves an upfront payment, additional regulatory and sales milestone payments, and tiered royalties based on future annual net sales. The specific financial figures were not disclosed, but these payments are structured to align incentives for both parties.
- Product Details: LNZ100 is a once-daily prescription eye drop indicated for presbyopia. Its active ingredient, aceclidine, is a novel small molecule acetylcholine receptor agonist designed to improve near vision without affecting distance vision, potentially making it superior to existing treatments.
- Regulatory Status: LNZ100 (marketed as VIZZ in the U.S.) received FDA approval in July 2025 and was commercially launched in the U.S. in October 2025. In China, the New Drug Application (NDA) was submitted in September 2025, with regulatory approval anticipated in the first quarter of 2027.
- Strategic Importance: This transaction is expected to significantly expand Everest’s product portfolio, strengthen its position in ophthalmology, and create strategic synergies across its business units.
- Market Opportunity: Presbyopia represents a significant unmet medical need in China, and LNZ100 has the potential to be a best-in-class, non-invasive therapy for this condition.
- Transaction Size: The highest applicable ratio in respect of the transaction is below 5%, thus exempting it from reporting, announcement, and shareholders’ approval requirements under Chapter 14 of the Hong Kong Listing Rules.
- Competitive Differentiation: Aceclidine’s unique pupil-selective mechanism allows for effective improvement in near vision without the “myopic shift” (distance vision impairment) seen with other miotics, broadening its utility to a wider range of patients, including older presbyopes.
- Pipeline and Partners: CORXEL, Everest’s partner in this deal, is a clinical-stage biopharmaceutical company with a focus on cardiometabolic diseases and a strong track record in drug development and licensing.
- Leadership Statement: The deal was announced by Chairman and Executive Director Yifang Wu, and the board comprises a mix of executive, non-executive, and independent non-executive directors.
Potential Price Sensitive Information for Shareholders
- The exclusive licensing and commercialization rights for LNZ100 in Greater China could materially enhance Everest’s ophthalmology portfolio and revenues, especially if the drug is successfully approved in early 2027.
- The structured nature of the deal—upfront payment, milestones, and royalties—reduces initial financial risk for Everest, while providing upside potential if LNZ100 meets commercial success.
- LNZ100’s differentiated profile (improving near vision without compromising distance vision) could allow it to capture significant market share over older therapies, representing a notable competitive advantage.
- With the U.S. approval and launch already achieved, and the NDA submission in China completed, the regulatory risk is somewhat mitigated, but investors should monitor for approval timelines and launch execution.
- As presbyopia is a large, underserved market in China, successful approval and commercialization could drive material growth for Everest, potentially impacting share price positively.
Product and Partner Details
LNZ100 was developed by LENZ Therapeutics (Nasdaq: LENZ) and is formulated with aceclidine, a miotic that achieves optimal pupil diameter to improve near vision, targeting a diameter below 2 mm without impairing distance vision—a limitation of other miotics like pilocarpine and carbachol.
CORXEL, Everest’s partner, acquired Greater China rights for LNZ100 in April 2022 and is a well-established, clinical-stage company with a pipeline spanning cardiometabolic drugs and innovative small molecules.
Leadership and Governance
The announcement was made by Everest’s Chairman and Executive Director Yifang Wu on 8 June 2026. The company’s board includes a mix of executive, non-executive, and independent non-executive directors, providing robust governance.
Conclusion
In summary, Everest Medicines’ exclusive agreement with CORXEL to commercialize LNZ100 in Greater China represents a strategically significant development that could materially benefit the company’s market position and financial performance. The transaction structure is shareholder-friendly, balancing risk and reward, and the product’s differentiated clinical profile opens up a large commercial opportunity. Shareholders should closely monitor regulatory progress and commercial execution as key upcoming catalysts.
Disclaimer: The information provided above is a summary of a public disclosure by Everest Medicines Limited. This article does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The article may contain forward-looking statements subject to risks and uncertainties.
珠三角地區版（粵語）
投資者重點摘要
- 獨家協議簽署： Everest Medicines Limited（Everest）於2026年6月5日與Corxel Pharmaceuticals Hong Kong Limited（Corxel全資子公司）簽署獨家協議，獲得LNZ100於大中華區（包括中國內地、香港、澳門及台灣）開發、生產及商業化的專屬權利。
- 財務條款： Everest將支付首期款項、監管及銷售里程碑款項，並按未來年銷售額支付分級權利金。具體金額未披露，但結構設計有利雙方激勵。
- 產品詳情： LNZ100為每日一次的處方眼藥水，用於治療老花眼。其活性成分aceclidine是一種新型乙酰膽鹼受體激動劑，能改善近距離視力，並避免影響遠距離視力，潛在優於現有療法。
- 監管進展： LNZ100（美國註冊名為VIZZ）已於2025年7月獲美國FDA批准，2025年10月在美國上市。中國方面，已於2025年9月提交新藥上市申請（NDA），預計2027年第一季度獲批。
- 戰略重要性： 該交易將大幅擴展Everest產品組合，強化其眼科領域地位，並提升公司整體戰略協同效應。
- 市場機遇： 老花眼在中國屬龐大未被滿足的醫療需求，LNZ100有潛力成為同類最佳的非侵入性療法。
- 交易規模： 該交易涉及的最高適用比例低於5%，因此根據香港上市規則第14章，無需公告及股東批准。
- 競爭優勢： Aceclidine的獨特機制能改善近視力，同時避免因瞳孔收縮導致的遠視力損失，適用人群更廣，包括年長患者。
- 合作夥伴及管線： CORXEL是一家專注心代謝病臨床階段的生物製藥公司，具備豐富的新藥研發及授權經驗。
- 公司管理層： 公告由董事會主席兼執行董事吳一方先生發佈，董事會構成多元，具備專業治理能力。
股東需留意的潛在股價敏感事項
- 今次獨家授權LNZ100有望顯著提升Everest的眼科產品組合及收入，若2027年獲批，可為公司帶來實質增長。
- 分期付款及權利金設計，有效降低Everest初期財務風險，產品上市後則有望帶來可觀利潤。
- LNZ100臨床優勢顯著，有望搶佔現有治療市場份額，提升競爭力。
- 美國已獲批上市，NDA已遞交中國，監管風險相對較低，未來關鍵是審批進度及商業執行。
- 老花眼市場巨大，若產品成功落地，對Everest股價或構成積極推動。
產品及合作夥伴詳情
LNZ100由LENZ Therapeutics（納斯達克：LENZ）開發，活性成分aceclidine能有效收窄瞳孔至2毫米以下，改善近距離視力，並不影響遠距離視力，優勝於傳統藥物如毛果芸香鹼及卡巴膽鹼。
合作夥伴CORXEL於2022年4月取得LNZ100大中華區權利，為一家有豐富新藥研發及臨床經驗的生物科技公司。
管理層及管治
公告由Everest董事會主席兼執行董事吳一方先生於2026年6月8日發佈，董事會成員多元，具備專業管治能力。
總結
Everest與CORXEL簽署LNZ100大中華區獨家授權協議，屬於公司眼科領域的重大戰略動作，具備潛在實質財務及市場價值。交易結構平衡風險與回報，產品具備技術壁壘及市場潛力。建議股東持續關注監管進度及後續商業化執行作為主要催化劑。
免責聲明： 以上資訊摘自Everest Medicines Limited公開披露，不構成任何投資建議。投資者應自行作出盡職調查，並諮詢專業顧問。文中或含有前瞻性陳述，具不確定性及風險。
